Clinical trials involving follicular lymphoma patients treated in the first-line and relapsed settings
| Reference . | Dose regimen . | Response rate . | PFS . |
|---|---|---|---|
| First-line follicular lymphoma | |||
| Zucca et al9 | 15 mg /d with rituximab for 18 wk | OR, 82%; CR, 36% | Median, 5 y |
| Fowler et al10 | 20 mg/d days 1-21 (28-d cycle) with rituximab for up to 12 cycles. | OR, 98%; CR, 87% | Median not reached* |
| 3 y, 79% | |||
| Martin et al11 | 20-25 mg/d days 1-21 (28-d cycle) with rituximab for up to 12 cycles | OR, 95%; CR, 72% | 5.y, 72% |
| Morschhauser et al13 | 20 mg/d days 1-21 (28-d cycle) with rituximab ×6 cycles followed by 10 mg/d days 1-21 (28-d cycle) for 12 cycles in patients with confirmed or unconfirmed CR. | OR, 61%; CR, 48% | 3 y. 77% |
| Relapsed follicular lymphoma | |||
| Witzig et al15 | 25 mg/d day 1-21 (28-d cycle) for up to 52 wk | OR, 27%; CR, 9% | Median, 4.4 mo |
| Leonard et al17 | 15-25 mg/d day 1-21 (28-d cycle), with or without rituximab | Lenalidomide | Lenalidomide: |
| OR, 53%; CR, 20% | Median time to progression, 1.1 y | ||
| Lenalidomide+rituximab: | Lenalidomide+rituximab: | ||
| OR, 76%; CR, 39% | Median time to progression, 2 y | ||
| Chong et al16 | 10 mg daily with rituximab | OR, 65%; CR, 35% | Median, 16.5 mo |
| Andorsky et al19 | 20 mg/d, day 1-21 (28-d cycle), with rituximab for 12 cycles, followed by 1:1 randomization of patients with ≥ stable disease to maintenance lenalidomide 10 mg, d 1‐21, with rituximab vs rituximab alone | OR, 74%; CR, 46% (for induction phase) | Median, 0.2 mo |
| Leonard et al18 | 20 mg/d day 1-21 (28-d cycle) with rituximab for 12 cycles | OR, 78%; CR, 34% | Median, 39.4 mo |
| Reference . | Dose regimen . | Response rate . | PFS . |
|---|---|---|---|
| First-line follicular lymphoma | |||
| Zucca et al9 | 15 mg /d with rituximab for 18 wk | OR, 82%; CR, 36% | Median, 5 y |
| Fowler et al10 | 20 mg/d days 1-21 (28-d cycle) with rituximab for up to 12 cycles. | OR, 98%; CR, 87% | Median not reached* |
| 3 y, 79% | |||
| Martin et al11 | 20-25 mg/d days 1-21 (28-d cycle) with rituximab for up to 12 cycles | OR, 95%; CR, 72% | 5.y, 72% |
| Morschhauser et al13 | 20 mg/d days 1-21 (28-d cycle) with rituximab ×6 cycles followed by 10 mg/d days 1-21 (28-d cycle) for 12 cycles in patients with confirmed or unconfirmed CR. | OR, 61%; CR, 48% | 3 y. 77% |
| Relapsed follicular lymphoma | |||
| Witzig et al15 | 25 mg/d day 1-21 (28-d cycle) for up to 52 wk | OR, 27%; CR, 9% | Median, 4.4 mo |
| Leonard et al17 | 15-25 mg/d day 1-21 (28-d cycle), with or without rituximab | Lenalidomide | Lenalidomide: |
| OR, 53%; CR, 20% | Median time to progression, 1.1 y | ||
| Lenalidomide+rituximab: | Lenalidomide+rituximab: | ||
| OR, 76%; CR, 39% | Median time to progression, 2 y | ||
| Chong et al16 | 10 mg daily with rituximab | OR, 65%; CR, 35% | Median, 16.5 mo |
| Andorsky et al19 | 20 mg/d, day 1-21 (28-d cycle), with rituximab for 12 cycles, followed by 1:1 randomization of patients with ≥ stable disease to maintenance lenalidomide 10 mg, d 1‐21, with rituximab vs rituximab alone | OR, 74%; CR, 46% (for induction phase) | Median, 0.2 mo |
| Leonard et al18 | 20 mg/d day 1-21 (28-d cycle) with rituximab for 12 cycles | OR, 78%; CR, 34% | Median, 39.4 mo |